

10/071,034

- 2 -

A0000417-01-CFP


AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

Claim 1 (currently amended). A method of treating ~~a disease or a disorder~~ responsive to inhibition of nuclear factor κ B (NF κ B) transcription factors rheumatoid arthritis, comprising administering to a patient in need thereof a sulfonylaminocarbonyl derivative, or a pharmaceutically acceptable salt thereof.

Claim 2 (currently amended). The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound of Formula I



or a pharmaceutically acceptable salt thereof, wherein:

X and Y are selected from oxygen, sulfur and $(\text{CR}'\text{R}'')_n$, wherein n is an integer

of from 1 to 4 and R' and R'' are each independently hydrogen, alkyl,

alkoxy, halogen, hydroxy, acyloxy, cycloalkyl, phenyl optionally

substituted or R' and R'' together form a spirocycloalkyl or a carbonyl;

with the proviso at least one of X and Y is $-(\text{CR}'\text{R}'')_n$ - and with the further

proviso when X and Y are both $(\text{CR}'\text{R}'')_n$ and R' and R'' are hydrogen and

n is one, R₁ and R₂ are aryl;

R is hydrogen, a straight or branched alkyl of from 1 to 8 carbon atoms or benzyl;

10/071,034

- 3 -

A0000417-01-CFP

R₁ and R₂ are each independently selected from:

- (a) phenyl or phenoxy each of which is unsubstituted or is substituted with from 1 to 5 substituents selected from:

phenyl,

an alkyl group having from 1 to 6 carbon atoms and which is straight or branched,

an alkoxy group having from 1 to 6 carbon atoms and which is straight or branched;

phenoxy,

hydroxy,

fluorine,

chlorine,

bromine,

nitro,

trifluoromethyl,

-COOH,

-COOalkyl wherein alkyl has from 1 to 4 carbon atoms and is straight or branched, and

-(CH₂)_pNR₃R₄, wherein p is zero or one, and each of R₃ and R₄ is selected from hydrogen or a straight or branched alkyl group having 1 to 4 carbon atoms;

- (b) 1- or 2-naphthyl unsubstituted or substituted with from 1 to 3 substituents selected from:

phenyl,

an alkyl group having from 1 to 6 carbon atoms and which is straight or branched,

an alkoxy group having from 1 to 6 carbon atoms and which is straight or branched;

hydroxy,

phenoxy,

fluorine,

chlorine,

bromine,

10/071,034

- 4 -

A0000417-01-CFP

nitro,

trifluoromethyl,

-COOH,

-COOalkyl wherein alkyl has from 1 to 4 carbon atoms and is straight or branched, and

-(CH₂)_pNR₃R₄, wherein p, R₃ and R₄ have the meanings defined above;

(c) arylalkyl;

(d) a straight or branched alkyl chain having from 1 to 20 carbon atoms and which is saturated or contains from 1 to 3 double bonds; and


(e) adamantyl or a cycloalkyl group wherein the cycloalkyl moiety has from 3 to 6 carbon atoms;

with the provisos:

(i) where X is (CH₂)_n, Y is oxygen, and R₁ is a substituted phenyl, then R₂ is a substituted phenyl;

(ii) where Y is oxygen, X is (CH₂)_n, R₂ is phenyl or naphthyl, then R₁ is not a straight or branched alkyl chain; and

(iii) the following compounds are excluded:

X	Y	R	R ₁	R ₂
CH ₂	O	H	(CH ₂)CH ₃	Ph
CH ₂	O	H	CH ₃	Ph
CH ₂	O	H		i-Pr

with the further proviso that compounds selected from the group consisting of:

Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)phenyl]propyl]-

2,6-bis(1-methylethyl)phenyl ester,

Sulfamic acid [fluoro[2,4,6-tris(1-methylethyl)phenyl]acetyl]-

2,6-bis(1-methylethyl)phenyl ester, and

Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(phenyl)phenyl ester

10/071,034

- 5 -

A0000417-01-CFP

are excluded.

Claim 3 (original). The method according to Claim 2, wherein the sulfonylaminocarbonyl derivative is a compound of Formula I, or a pharmaceutically acceptable salt thereof, selected from:

(1,2,3,4-Tetrahydro-naphthalene-2-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;

[Bis-(4-chloro-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

(Bromo-phenyl-acetyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxy-2,6-diisopropyl-phenyl ester;

Methyl-[(2,4,6-triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-nitro-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-fluoro-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-dimethoxy-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-amino-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,4,6-trimethoxy-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-tert-butyl-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetyl-2-isopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methoxy-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-dichloro-phenyl ester;

10/071,034

- 6 -

A0000417-01-CFP

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid dodecyl ester;
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-bromo-2,6-diisopropyl-phenyl ester;
[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methyl-phenyl ester;
[1-(4-Dimethylamino-phenyl)-cyclopentanecarbonyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;
[1-(4-Nitro-phenyl)-cyclopentanecarbonyl]-sulfamic acid 2,6-diisopropyl-phenyl ester;
3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy-benzoic acid methyl ester;
Sulfamic acid (phenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;
Sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;
Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;
Sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,4,6-tris(1-methylethyl)phenyl ester;
Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,4,6-tris(1-methylethyl)phenyl ester;
Sulfamic acid[adamantaneacetyl]-2,6-bis(1-methylethyl)phenyl ester;
Sulfamic acid[[2,6-bis(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt;
Sulfamic acid[[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester-sodium salt;
Sulfamic acid (decanoyl)-2,6-bis-(1-methylethyl)phenyl ester;
Sulfamic acid (dodecanoyl)-2,6-bis-(1-methylethyl)phenyl ester;
2,6-Bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]methyl]-sulfonyl]benzeneacetamide;
2,6-Bis(1-methylethyl)-N-[[[2,4,6-tris(1-methylethyl)phenyl]methyl]-sulfonyl]benzeneacetamide-sodium salt;

10/071,034

- 7 -

A0000417-01-CFP

2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris(1-methylethyl)phenyl]methyl]-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[[[2,4,6-tris(1-methylethyl)phenyl]methyl]-sulfonyl]carbamate-sodium salt;

Sulfamic acid (1-oxo-3,3-diphenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2,6-dichlorophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2,6-dichlorophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester sodium salt;

Sulfamic acid trans-[(2-phenylcyclopropyl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2,5-dimethoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2,4,6-trimethoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2,4,6-trimethylphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2-thiophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [3-thiophenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2-methoxyphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (oxophenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [2-trifluoromethylphenyl(acetyl)]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (1-oxo-2-phenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (cyclopentylphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (cyclohexylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (diphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (triphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

10/071,034

- 8 -

A0000417-01-CFP

Sulfamic acid [(1-phenylcyclopentyl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (1-oxo-2-phenylbutyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (cyclohexylphenylacetyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (1-oxo-2,2-diphenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [(9H-fluoren-9-yl)carbonyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (1-oxo-3-phenylpropyl)-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [1-oxo-3-[2,4,6-tris(1-methylethyl)phenyl]-2-propenyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [(acetyloxy)[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid [hydroxy[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl)-2,6-bis(1-methylethyl)phenyl ester sodium salt;

Sulfamic acid [[2,4,6-tris(1-methylethyl)phenoxy]acetyl]-2,6-bis(1-methylethyl)phenyl ester; and

Sulfamic acid [[2,6-bis(1-methylethyl)phenoxy]acetyl]-2,6-bis(1-methylethyl)phenyl ester.


Claim 4 (original). The method according to Claim 2, wherein the sulfonylaminocarbonyl derivative is sulfamic acid [[2,4,6-tris(1-methylethyl)phenyl]acetyl]-2,6-bis(1-methylethyl)phenyl ester, or a pharmaceutically acceptable salt thereof.

10/071,034

- 9 -

A0000417-01-CFP

Claim 5 (original). The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound of Formula II



or a pharmaceutically acceptable salt thereof, wherein:

R¹ is hydrogen, alkyl, or alkoxy;

R² to R⁵ are alkyl, alkoxy, or unsubstituted or substituted phenyl; and

R⁶ is -CN,

-(CH₂)₀₋₁-NR⁷R⁸,

-O-(CH₂)₁₋₁₀-Z, wherein Z is -NR⁹R¹⁰, OR¹, or CO₂R¹,

-OC(=O)R¹¹,

-SR¹¹,

-SCN,

-S(CH₂)₁₋₁₀Z,

-S(O)₁₋₂R¹², wherein R¹² is hydroxy, alkoxy, alkyl, (CH₂)₁₋₁₀Z or NR⁷R⁸,

-C(=O)XR¹¹, or

-CH₂-R¹³, wherein R¹³ is (CH₂)₀₋₅-Y-(CH₂)₀₋₅Z, or alkyl of from 1 to

20 carbons with from 1-3 double bonds, which alkyl is optionally substituted by one or more moieties selected from -CN, NO₂,

halogen, OR¹, NR⁹R¹⁰, and CO₂R¹;

wherein R⁷ and R⁸ are each independently selected from:

-hydrogen, at least one of R⁷ and R⁸ is other than hydrogen,





10/071,034

- 10 -

A0000417-01-CFP

$-(CH_2)_{1-10}Z$, wherein Z is as defined above and R^9 and R^{10} are each independently selected from hydrogen, alkyl, and unsubstituted or substituted phenyl, or

R^9 and R^{10} are taken together with the nitrogen to which they are attached to form a ring selected from:



wherein R^{14} , R^{15} , and R^{16} are each independently selected from hydrogen, alkyl, and unsubstituted or substituted phenyl;

$-C(=Q)XR^{11}$, wherein X is a bond or NH wherein Q is O or S, R^{11} is hydrogen, alkyl, unsubstituted or substituted phenyl,

$-(CH_2)_{0-5}-Y-(CH_2)_{0-5}Z$, wherein Z is as defined above and Y is phenyl or a bond;

$-C(=O)-CR^{17}R^{18}Z$;

$-C(=O)NHCR^{17}R^{18}Z$, wherein R^{17} and R^{18} are each independently hydrogen, alkyl, phenyl, substituted phenyl, or the side chain of a naturally occurring amino acid;





$-S(O)_{1-2}R^{19}$, wherein R^{19} is alkyl, unsubstituted or substituted phenyl, naphthyl, or a heteroaromatic ring, or NR^9R^{10} or

R^7 and R^8 are taken together with the nitrogen to which they are attached to form a ring selected from:

10/071,034

- 11 -

A0000417-01-CFP



[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-formyl-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-cyano-vinyl)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(4-methyl-piperazin-1-ylmethyl)-phenyl ester, dihydrochloride;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[bis-(2-hydroxy-ethyl)-amino]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(3-phenyl-thioureido)-phenyl ester; and

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-sulfamoyl-phenyl ester

are excluded.

Claim 6 (original). The method according to Claim 5, wherein the sulfonylaminocarbonyl derivative is a compound of Formula II, or a pharmaceutically acceptable salt thereof, selected from:

6-(3,5-Diisopropyl-4-{[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy}-phenyl)-hexanoic acid ethyl ester;

10/071,034

- 12 -

A0000417-01-CFP

3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid ethyl ester;

{[4-(1-Hydroxy-1-methyl-ethyl)-2,6-diisopropyl-phenyl]-acetyl}-sulfamic acid 2,6-diisopropyl-phenyl ester;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-4-methyl-pentanoylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-tert-butyl-ureido)-2,6-diisopropyl-phenyl ester;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propionylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-cyano-vinyl)-2,6-diisopropyl-phenyl ester;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-hydroxy-propionylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-4-carbamoyl-butyrylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;

[2-(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-((S)-2-amino-3-methyl-butyrylamino)-2,6-diisopropyl-phenyl ester; compound with trifluoroacetic acid;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(3,5-dichlorophenyl)-thioureido]-2,6-diisopropyl-phenyl ester;

(S)-[5-tert-Butoxycarbonylamino-5-(3,5-diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenylcarbamoyl]-pentyl]-carbamic acid tert-butyl ester;

(S)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2,6-diaminohexanoylamino)-2,6-diisopropyl-phenyl ester dihydrochloride;

10/071,034

- 13 -

A0000417-01-CFP

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-acetyl-amino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-acetyl-amino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-t-butoxycarbonylamino-4-methylsulfanyl-butyl-amino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-4-methylsulfanyl-butyl-amino)-2,6-diisopropyl-phenyl ester trifluoroacetate;

3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid ethyl ester;

3-[3-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl]-ureido]-propionic acid;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[2-amino-3-(1H-indol-3-yl)-propionyl-amino]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(5-amino-pentanoyl-amino)-2,6-diisopropyl-phenyl ester trifluoroacetate(1:1)(salt);

(D)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-propionyl-amino)-2,6-diisopropyl-phenyl ester trifluoroacetate(1:1)(salt);

(L)-[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-propionyl-amino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-amino-2-methyl-propionyl-amino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-dimethylamino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(3-amino-propoxy)-2,6-diisopropyl-phenyl ester hydrochloride salt;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-thiocyanato-phenyl ester;

10/071,034

- 14 -

A0000417-01-CFP

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-cyano-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[(2-amino-acetylamino)-methyl]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(benzylamino-methyl)-2,6-diisopropyl-phenyl ester mono hydrochloride;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-carbamoyl-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-hydroxymethyl-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-acetylamino-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(2-hydroxy-ethylamino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-[3-(2,6-diisopropyl-phenyl)-ureido]-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(3-phenyl-ureido)-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-(thiophene-2-sulfonylamino)-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 4-(5-dimethylamino-naphthalene-1-sulfonylamino)-2,6-diisopropyl-phenyl ester;

[(2,4,6-Triisopropyl-phenyl)-acetyl]-sulfamic acid 2,6-diisopropyl-4-methanesulfonylamino-phenyl ester;

6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-hexanoic acid ethyl ester; and

6-(3,5-Diisopropyl-4-[(2,4,6-triisopropyl-phenyl)-acetyl]sulfamoyloxy)-phenyl)-hexanoic acid.

10/071,034

- 15 -

A0000417-01-CFP

Claim 7 (original). The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

(9H-Xanthene-9-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;
((E)-2-Methyl-3-phenyl-acryloyl)-sulfamic acid 2,6-diisopropyl-phenyl ester; and
(2-Oxo-2H-chromene-3-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester.

Claim 8 (original). The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;
Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-hydroxyphenyl ester;
Carbamic acid, [(phenylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester;
Carbamic acid, [(didecylamino)sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester;
Carbamic acid, [[bis(1-methylethyl)amino]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;
Carbamic acid, [(dipentylamino)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;
Carbamic acid, [[[diphenylmethyl)amino]sulfonyl]methyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester;
DL-Tryptophan, α -methyl-N-[[[(tricyclo[3.3.1.1^{3,7}]dec-2-yloxy)carbonyl]amino]sulfonyl]-, methyl ester;
Carbamic acid, sulfonylbis-, bis[2,6-bis(1-methylethyl)phenyl] ester;
Carbamic acid, [[[2-(phenylmethyl)phenyl]amino]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester;

10/071,034

- 16 -

A0000417-01-CFP

Methyl[[2,6-bis(1-methylethyl)phenyl amino]sulfonyl]carbamate;
Dodecyl[[[2,6-bis(1-methylethyl)phenyl]
amino]sulfonyl]carbamate;
2,6-Bis(1,1-dimethylethyl)-4-methoxyphenyl [(2,2-diphenylethyl)-
amino]sulfonyl]carbamate;
2,6-Bis(1,1-dimethylethyl)-4-methoxy phenyl [[[2,6-bis(1-methylethyl)-
phenyl]amino]sulfonyl]carbamate;
2,6-Bis(1,1-dimethylethyl)phenyl-[[[(diphenylmethyl)amino]-
sulfonyl]carbamate;
2,6-Bis(1,1-dimethylethyl)phenyl [[[2,6-bis(1-methylethyl)phenyl]amino]-
sulfonyl] carbamate;
2,6-Bis(1,1-dimethylethyl)phenyl [(2,2-diphenylethyl)amino]sulfonyl]-
carbamate;
2,6-Bis(1,1-dimethylethyl)phenyl [[bis(phenylmethyl)amino]sulfonyl]-
carbamate;
2,6-bis(1-methylethyl)phenyl[(diphenyl-amino)sulfonyl]carbamate;
2,6-Bis(1-methylethyl)phenyl[(dibutyl-amino)sulfonyl]carbamate;
2,6-Bis(1-methylethyl)phenyl[[bis(phenyl-methyl)amino]sulfonyl]-
carbamate;
2,6-Bis(1-methylethyl)phenyl[(1H-benzimidazol-2-ylamino)sulfonyl]-
carbamate;
2,6-Bis(1-methylethyl)phenyl[[[(2,2-diphenylethyl)amino]sulfonyl]-
carbamate;
2,6-Bis(1-methylethyl)phenyl[[[2,6-bis(1-methylethyl)phenyl]amino]-
sulfonyl]carbamate;
2,6-Bis(1-methylethyl)phenyl[[[(diphenyl-methyl)amino]sulfonyl]-
carbamate;
2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[(diphenylmethyl)amino]-
sulfonyl]carbamate;
2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[2,6-bis(1-methylethyl)-
phenyl]amino]sulfonyl]carbamate;

10/071,034

- 17 -

A0000417-01-CFP

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[((2,2-diphenylethyl)amino)-sulfonyl]-carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dibutylamino)sulfonyl]-carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dipentylamino)sulfonyl]-carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[bis(1-methylethyl)amino]-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dihexylamino)sulfonyl]-carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(hexylamino)sulfonyl]-carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[methyl(2-phenylethyl)-amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[bis-3-(dimethylamino)-propyl]amino]-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(methyl octyl amino)-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-[[bis[(tetrahydro-2-furanyl)methyl]-amino]sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dioctylamino)sulfonyl]-carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[methyl 2-(2-pyridinyl)-ethyl]amino]sulfonyl]carbamate, hydrochloride salt;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[[[methyl 2-(2-pyridinyl)-ethyl]amino]-sulfonyl]carbamate, sodium salt;

2,6-Bis(1,1-dimethylethyl)-4-methyl-phenyl[(dodecylamino)sulfonyl]-carbamate;

2,6-Bis(1-methylethyl)phenyl[[bis(1-methylethyl)amino]sulfonyl]-carbamate;

10/071,034

- 18 -

A0000417-01-CFP

2,6-Bis(1-methylethyl)phenyl[((1-methylethyl)phenylmethyl)amino]-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(hexyl-amino)sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(dioctyl-amino)sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[[cyclo-hexyl(1-methylethyl)amino]-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(methyl-octylamino)sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(dihexyl-amino)sulfonyl]carbamate;

Dodecyl[(2,4,6-trimethoxyphenyl)amino]-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl ester(4-morpholinylsulfonyl)carbamic acid;

2,6-Bis(1-methylethyl)phenyl ester(1-piperidinylsulfonyl)carbamic acid;

2,6-Bis(1-methylethyl)phenyl ester(1-pyrrolidinylsulfonyl)carbamic acid;

2,6-Bis(1-methylethyl)phenyl ester[(2,3-dihydro-1H-indol-1-yl)sulfonyl]-carbamic acid;

2,6-Bis(1-methylethyl)phenyl[(dibutylamino)sulfonyl]carbamate monosodium salt; and

2,6-Bis(1,1-dimethylethyl)phenyl[((diphenylmethyl)amino)-sulfonyl]-methyl carbamate.

Claim 9 (original). The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

Urea, N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dipropylamino)-sulfonyl]-;

Urea, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-N'-

[[[(tricyclo[3.3.1.1^{3,7}]dec-1-ylmethyl)amino]sulfonyl]-, (4S-*cis*)-;

Urea, N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-N'-[[[(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)amino]sulfonyl]-, stereoisomer;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(1-methylethyl)amino]-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[(diphenylmethyl)amino]-sulfonyl]urea;

10/071,034

- 19 -

A0000417-01-CFP

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diphenylamino)-sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dibutylamino)sulfonyl]urea;
N-[[[2,6-bis(1-methylethyl)phenyl]amino]-sulfonyl]-N'-
(diphenylmethyl)urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[2,6-bis(1-methylethyl)-
phenyl]amino]sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[2,2-diphenylethyl)-
amino]sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(9H-fluoren-9-ylamino)-sulfonyl]-
urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(phenylmethyl)amino]-
sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[1-methylethyl)-(phenylmethyl)-
amino]sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dioctylamino)sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(4-phenyl-1-piperidinyl)-sulfonyl]-
urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dihexylamino)sulfonyl]-urea;
N-[[bis[3-(dimethylamino)propyl]amino]-sulfonyl]-N'-[2,6-bis(1-
methylethyl)phenyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(hexylamino)sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis-[(tetrahydro-2-
furanyl)methyl]amino]sulfonyl]-urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diethylamino)sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyloctyl amino)sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[cyclohexyl(1-methylethyl)amino]-
sulfonyl]urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dipentylamino)sulfonyl]-urea;
N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(2-methylpropyl)amino]-
sulfonyl]urea;

10/071,034

- 20 -

A0000417-01-CFP

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[ethyl(2-propenyl)amino]-sulfonyl]-urea;

N-[[bis(3-methylbutyl)amino]sulfonyl]-N'-[2,6-bis(1-methylethyl)-phenyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(didecylamino)sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(didodecylamino)-sulfamoyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(diisopropylamino)-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dicyclohexylamino)-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyloctadecylamino)-sulfonyl]-urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(di-2-propenylamino)-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[[(1,1-dimethylethyl)(1-methylethyl)amino]sulfonyl]-urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[[bis(1-methylpropyl)amino]-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(methyltetradecylamino)-sulfonyl]urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-pyrrolidinylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-piperidinylsulfonyl)urea;

N'-[[[2,6-bis(1-methylethyl)phenyl]amino]sulfonyl]-N,N-bis(phenylmethyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(dibutylamino)sulfonyl]urea, monosodium salt; and

N'-[2,6-bis(1-methylethyl)phenyl]-N-methyl-[(dibutylamino)sulfonyl]urea.

Claim 10 (original). The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

10/071,034

- 21 -

A0000417-01-CFP

Sulfamic acid, [[[2,4,6-tris(1-methylethyl)phenyl]amino]-carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Sulfamic acid, [[[[1-[4-(dimethylamino)phenyl]cyclopentyl]-methyl]amino]carbonyl], 2,6-bis(1-methylethyl)phenyl ester;

(2,3-Dihydro-indole-1-carbonyl)-sulfamic acid 2,6-diisopropyl-phenyl ester;

Sulfamic acid, [[(triphenylmethyl)amino]carbonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Octadecyl [[[2,6-bis(1-methylethyl)phenyl]-amino]carbonyl]sulfamate;

Dodecyl-N-[[[2,6-bis(1-methylethyl)phenyl]-amino]carbonyl]sulfamate;

Decyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]sulfamate;

(±) 1-Methylheptyl [[[2,6-bis(1-methylethyl)phenyl]amino]-carbonyl]sulfamate;

2,6-Bis(1-methylethyl)phenyl [[[2,6-bis(1-methylethyl)-phenyl]amino]carbonyl]sulfamate;

(±) 1-Methylundecyl [[[2,6-bis(1-methylethyl)phenyl]amino]-carbonyl]sulfamate; and

Dodecyl [[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]-sulfamate; sodium salt.

Claim 11 (original). The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

Carbamic acid, [(dodecyloxy)sulfonyl]-, dodecyl ester;

Carbamic acid, [(dodecyloxy)sulfonyl]-, [1,1':3',1''-terphenyl]-2'-yl ester;

Carbamothioic acid, [(dodecyloxy)sulfonyl]-, S-[2,6-bis(1-methylethyl)-phenyl] ester;

Carbamic acid, (phenoxysulfonyl)-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [(2,6-dimethylphenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

10/071,034

- 22 -

A0000417-01-CFP

Carbamic acid, [[2,6-bis(1,1-dimethylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1,1-dimethylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [(2,6-difluorophenoxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [(hexadecyloxy)sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-dimethoxyphenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1-methylheptyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)-4-nitrophenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1,2-ethanediyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 1,2,3-propanetriyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-bromo-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, [1,1':3',1''-terphenyl]-2'-yl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methoxyphenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluoro-2,3,5,6-tetrakis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-chloro-2,6-bis-(1-methylethyl)phenyl ester;

Stigmasta-5,22-dien-3-ol, [[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]-carbamate, (3 α)-;

10/071,034

- 23.-

A0000417-01-CFP

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1,1-dimethylethyl)-4-methylphenyl ester;

Stigmastan-3-ol, [[2,7-bis(1-methylethyl)phenoxy]sulfonyl]-carbamate, (3 α)-;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-methoxy-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-tris(1-methylethyl)phenyl ester;

Carbamic acid, [[2,4,6-tris(1-methylethyl)phenoxy]sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,4,6-tris(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-tris(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4,6-tris(1,1-dimethylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-[[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]dithio]-2,6-bis(1,1-dimethylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-[(dimethylamino)methyl]-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, tricyclo[3.3.1.1^{3,7}]dec-2-yl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-hydroxy-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, cyclohexyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 3,3',5,5'-tetrakis(1-methylethyl)[1,1'-biphenyl]-4,4'-diyl ester;

Carbamic acid, [[4-hydroxy-2,6-bis(1-methylethyl)phenoxy]-sulfonyl]-, 2,6-bis(1-methylethyl)phenyl ester;

10/071,034

- 24 -

A0000417-01-CFP

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, tricyclo[3.3.1.1^{3,7}]dec-1-yl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2-(1,1-dimethylethyl)-6-methylphenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 5-methyl-2-(1-methylethyl)cyclohexyl ester;

Carbamothioic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, S-[2,6-bis(1-methylethyl)phenyl] ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2,6-diethylphenyl)methyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2*S*,6*S*)-2,6-bis(1-methylethyl)cyclohexyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-(1,1-dimethylethyl)-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluorophenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,4-difluorophenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, pentafluorophenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-difluorophenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, (2*R*,6*S*)-2,6-bis(1-methylethyl)cyclohexyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,3,5,6-tetramethylphenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 3-pyridinyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 2,6-dimethylphenyl ester;

10/071,034

- 25 -

A0000417-01-CFP

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-acetyl-2,6-bis(1-methylethyl)phenyl ester;

Carbamic acid, [[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-, 4-fluoro-2,6-bis(1-methylethyl)phenyl ester;

2,6-Bis(1-methylethyl)phenyl[[2,6-bis(1-methylethyl)phenoxy]sulfonyl]-carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl(phenoxy-sulfonyl)-carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(hexyloxy)-sulfonyl]carbamate;

2,6-Bis(1,1-dimethylethyl)-4-methylphenyl[(dodecyloxy)-sulfonyl]carbamate;

Dodecyl[[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]carbamate;

Methyl[[2,6-bis(1-methylethyl)phenoxy]-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(hexyloxy)-sulfonyl]carbamate;

2,6-Bis(1-methylethyl)phenyl[(dodecyloxy)-sulfonyl]carbamate; and

2,6-Bis(1,1-dimethylethyl)phenyl[[2,6-bis(1-methylethyl)-phenoxy]-sulfonyl]carbamate.

Claim 12 (original). The method according to Claim 1, wherein the sulfonylaminocarbonyl derivative is a compound, or a pharmaceutically acceptable salt thereof, selected from:

N-[2,6-bis(1-methylethyl)phenyl]-N'-[(6-ethoxy-2-benzothiazolyl)-sulfonyl]-urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-octadecylsulfonyl)urea;

N-[2,4,6-trimethoxyphenyl]-N'-(2-octadecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(tetradecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(dodecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(hexadecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-methyl-N'-(dodecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(tridecylsulfonyl)urea;

N-[2,4,6-trimethoxyphenyl]-N'-(hexadecylsulfonyl)urea;

10/071,034

- 26 -

A0000417-01-CFP

N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-methyl-2-pentadecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenyl-1-tetradecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(dodecylsulfonyl)urea;

N-[2,6-bis(1-methylethyl)phenyl]-N'-(1-phenyl-1-nonylsulfonyl)urea; and

N-[2,6-bis(1-methylethyl)phenyl]-N'-(2-decylsulfonyl)urea.

Claims 13 to 30 (cancelled).